Ultragenyx Pharmaceutical (RARE) Research & Development (2016 - 2025)
Historic Research & Development for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $216.2 million.
- Ultragenyx Pharmaceutical's Research & Development rose 2710.2% to $216.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $734.5 million, marking a year-over-year increase of 951.75%. This contributed to the annual value of $697.9 million for FY2024, which is 762.06% up from last year.
- According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Research & Development is $216.2 million, which was up 2710.2% from $164.7 million recorded in Q2 2025.
- Over the past 5 years, Ultragenyx Pharmaceutical's Research & Development peaked at $237.3 million during Q3 2022, and registered a low of $113.2 million during Q2 2021.
- In the last 5 years, Ultragenyx Pharmaceutical's Research & Development had a median value of $164.7 million in 2025 and averaged $162.9 million.
- In the last 5 years, Ultragenyx Pharmaceutical's Research & Development surged by 10922.52% in 2022 and then plummeted by 3373.49% in 2023.
- Over the past 5 years, Ultragenyx Pharmaceutical's Research & Development (Quarter) stood at $123.0 million in 2021, then surged by 38.85% to $170.8 million in 2022, then decreased by 6.0% to $160.6 million in 2023, then rose by 16.95% to $187.8 million in 2024, then increased by 15.15% to $216.2 million in 2025.
- Its Research & Development stands at $216.2 million for Q3 2025, versus $164.7 million for Q2 2025 and $165.8 million for Q1 2025.